Razi Cov Pars

Razi Cov Pars is an inactivated vaccine developed by the Razi Vaccine and Serum Research Institute for the prevention of COVID-19. The vaccine is currently in the third phase of clinical trials and has been authorized for emergency use in Iran.

Development

The development of Razi Cov Pars began in early 2020, following the global outbreak of the COVID-19 pandemic. The Razi Vaccine and Serum Research Institute, a leading biomedical research center in Iran, spearheaded the project. The vaccine is an inactivated vaccine, which means it contains a virus that has been killed or weakened so it cannot cause disease.

Clinical Trials

Razi Cov Pars has undergone three phases of clinical trials. The first phase began in February 2021, with the second phase following in April 2021. The third phase of trials began in June 2021 and is currently ongoing. Preliminary results from the trials have shown the vaccine to be safe and effective in preventing COVID-19.

Authorization

In August 2021, Razi Cov Pars was granted emergency use authorization by the Iranian Ministry of Health and Medical Education. This allows the vaccine to be used in Iran while the final stages of clinical trials are completed.

Efficacy

While the final results of the clinical trials are not yet available, preliminary data suggests that Razi Cov Pars is effective in preventing COVID-19. The vaccine has shown a strong immune response in trial participants, with minimal side effects reported.

Distribution

Following its emergency use authorization, Razi Cov Pars is being distributed across Iran. The vaccine is expected to play a key role in Iran's COVID-19 vaccination campaign.

See Also

• COVID-19 vaccine
• COVID-19 pandemic in Iran
• Razi Vaccine and Serum Research Institute